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A 32-year-old Hispanic male, with a 5-year history of tran- 
sitional cell carcinoma in situ of the bladder, was admit- 
ted with rigors, fever of 4O”C, scleral icterus, and 
abdominal pain. Three days prior to admission he had 
received his first intravesical irrigation with bacille Cal- 
mette-Gubin (BCG) vaccine. The bladder irrigation pro- 
ceeded uneventfully. However, at the time of his first 
voiding, approximately 2 hours after BCG instillation, 
chills, headache, and dizziness were noted. Symptoms per- 
sisted and worsened, and fever was noted. The patient 
presented to the emergency room for evaluation 72 hours 
after bladder irrigation and was admitted to hospital. 
The patient was born in the United States and had no 
history of foreign travel. He works in an office setting for 
an international auction house but does not handle auc- 
tioned items. He lives with his girlfriend who is in good 
health. His tuberculin status and human immunodeficiency 
virus (HIV) status were unknown on admission, but both 
were subsequently shown to be negative. His only previ- 
ous hospitalizations were for diagnosis of the transitional 
cell carcinoma in situ of the bladder, which was diagnosed 
during his first evaluation of hematuria, and for ambula- 
tory cystoscopic fulgurations of the bladder over the past 
5 years; the latest, more than 6 months prior to BCG 
immunotherapy He had no other known underlying med- 
ical problems and took no chronic medications. 
On admission to hospital, the patient’s physical exam- 
ination was significant for tachycardia, drenching sweats, 
blood pressure of 90/60 mmHg, a clear auscultatory chest 
examination, a hemic I-VI systolic ejection murmur, a 
benign abdominal examination, and a normal neurologic 
examination. A hemogram revealed a white blood cell 
count (WBC) of 6000, a hematocrit of 45%, and a platelet 
count of 155,000. The WBC comprised 72% neutrophils, 
10% lymphocytes, 3% monocytes, and 15% bands. Blood 
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chemistry values were normal except for a mildly ele- 
vated lactate dehydrogenase (LDH) of 279 IU/L (normal 
range, loo-225 IU/L), an aspartate aminotransferase (AST) 
of I61 IU/L (normal range, 7-40 IU/L), and a serum ala- 
nine aminotransferase (AIX’) of I65 IU/L (normal range, 
10-60 IU/L). Total bilirubin was 3.0 mg/dL (normal range, 
0.2-l .2 mg/dL), and gamma-glutamyl transpeptidase 
(GGTP) was 165 IU/L (normal range, 7-64 IU/L). A urine 
analysis revealed yellow, clear urine with a pH of 7, with 
no white or red blood cells. After appropriate cultures, 
antibiotic therapy was begun with cefazolin, and intra- 
venous fluids were administered. A working diagnosis of 
acute hepatitis or sepsis was entertained. 
Over the next 48 hours the patient’s condition dete- 
riorated, and he required transfer to the intensive care 
unit (KU) for therapy of apparent septic shock. An ini- 
tial chest radiograph was negative, but a subsequent gal- 
lium scan was consistent with diffuse pneumonitis 
(Figure 1). Evaluations for hepatitis A, B, and C were all 
negative. Fever and hepatitis persisted. All routine cul- 
tures remained negative. Chest radiograph obtained dur- 
ing the patient’s confinement to the ICU revealed bilateral 
lower lobe infiltrates (Figure 2). 
HOSPITAL COURSE 
On admission, the differential diagnosis included sepsis, 
pneumonia, acute hepatitis, and urosepsis as a cause for 
Figure 1. Anterior and posterior gallium scans showing a diffuse uptake 
in all lung fields and increased uptake in the liver. 
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Figure 2. Chest radiograph taken during stay in the ICU showing bi- 
lateral lower lobe oneumonia. 
multiorgan failure. However, initial and subsequent urine 
analyses were normal, and all routine cultures of the 
blood and urine were sterile. Initially, complications from 
the BCG therapy were thought to be unlikely, because 
urine analyses were normal, systemic signs and symp- 
toms predominated, this was the first instillation of the 
BCG, there was no evidence of previous erosive cystitis, 
and the procedure itself was uncomplicated. Multiple 
organ system involvement initially pointed toward sepsis 
from more common gram-negative pathogens that would 
be associated with any urologic procedure. However, all 
routine cultures were being reported negative and mul- 
tiple organ system failure and diffuse intravascular coag- 
ulopathy ensued. Treatment required ventilatory support 
for pulmonary insufficiency, hemodialysis for acute renal 
failure, and multiple transfusions of blood prsoducts for 
treatment of disseminated intravascular coagulation and 
concurrent upper gastrointestinal bleeding. A clinical diag- 
nosis of BCG sepsis (disseminated BCG infection with 
Figure 3. Low-power photomicrograph of liver biopsy (H8(E) on day 21 
of therapy showing multiple granulomas in the liver parenchyma 
(arrows). 
Figure 4. High-power photomicrograph of liver granuloma (H&E) show- 
ing typical multinucleated giant cells. 
multiple system failure: pulmonary, hepatic, renal) was 
assumed, and treatment was initiated with isoniazid and 
rifampin. Ethambutol was added subsequently when oral 
feeding was instituted. 
Acute renal failure with the blood urea nitrogen ris- 
ing to 112 mg/dL (normal range, lo-26 mg/dL), and the 
creatinine to 12 mg/dL (normal range, 0.5-1.4 mg/dL) 
required 5 days of hemodialysis. An acute bleeding duo- 
denal ulcer and diffuse gastritis were diagnosed by 
endoscopy. Antibiotic treatment during this time was 
expanded to include vancomycin and imipenem. The 
patient was supported with transfusions of fresh frozen 
plasma (29 units), packed red blood cells (28 units), 
platelets (8 units), and cryoprecipitate (12 units). Severe 
metabolic acidosis, with the serum CO, dropping to 
2.9 mEq/L (normal range, 24-32 mEq/L) required cor- 
rection with intravenous bicarbonate. A liver biopsy, per- 
formed on day 2 1 after starting anti-mycobacteria therapy, 
revealed a granulomatous hepatitis with no acid-fast bacilli 
seen (Figures 3 and 4). Chest radiographs remained con- 
sistent with diffuse pneumonitis. Over the next 7 days 
the patient slowly improved; renal, hepatic, and pul- 
monary functions normalized, and he was discharged 
33 days after hospital admission. 
ETIOLOGIC IDENTIFICATION 
Seven weeks after admission, cultures of blood but not of 
urine were reported to be growing an acid-fast bacillus 
(APB). The blood isolate and an isolate from a BCG vac- 
cine companion vial were sent to the Centers for Dis- 
ease Control and Prevention (CDC) for identification. 
Analysis by high-performance liquid chromatography 
(HPLC) revealed that both isolates had the identical pat- 
terns of BCG strains that identify the isolates as distinct 
from virulent Mycobacterium tuberculosis or Mycobac- 
terium bouis (l?gure 5).’ The HPLC clearly identified the 
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Figure 5. High-performance liquid chromatography showing identi- 
cal patterns for the companion vial BCG isolate (A) and the blood 
BCG isolate (ES). 
blood isolate as identical to the isolate used for the ini- 
tial bladder irrigation in this patient. Although the pre- 
sumed portal of entry for the BCG would be the bladder, 
urine analyses were normal and both routine and AFB 
cultures of the urine were negative. 
Iseman, at the National Jewish Center in Denver, iden- 
tified the strain used for immunotherapy (companion 
vial) and the organism recovered from the patient’s blood 
culture both as it4 bovis and showed that the two organ- 
isms had identical anti-mycobacterial sensitivity profiles 
(i.e., sensitive to isoniazid, rifampin, ethambutol, strepto- 
mycin, capreomycin, kanamycin, amikacin, and cycloserine) 
at all concentrations tested. Both isolates demonstrated a 2% 
resistance top-aminosalicylic acid (PAS) when tested at the 
8.0 pg concentration. 
Because of the question of an abnormal host 
response to the initial bladder irrigation, immunologic 
evaluation was performed. The patient had, and contin- 
ues to have multiple normal CD4 and CDS cell studies. 
His purified protein derivative (PPD) converted to posi- 
tive for the first year and then reverted to negative (a 
usual finding after BCG vaccination). A T-year follow-up 
period has elapsed, during which time he has remained 
well, and remains HIV-l negative. Follow-up cystoscopies 
and biopsies have remained negative and no further BCG 
immunotherapy has been required. 
DISCUSSION 
Bacille Calmette-Guerin immunotherapy of carcinoma in 
situ of the bladder was first reported by Morales et al in 
1976,2 and since then thousands of patient treatment 
courses have confirmed that BCG immunotherapy is 
effective and relatively safe. Serious adverse reactions to 
BCG immunotherapy rarely are reported; the treatment 
is usually well tolerated.3 Most reported complications 
have been minor and self-limited; systemic complications 
occur only occasionally.* Localized reactions, such as gran- 
ulomatous tuberculous epididymo-orchitis,5 granuloma- 
tous prostatitis6 and BCG pyelonephritis,’ have been 
reported. The systemic complications reported have 
included granulomatous hepatitis8 the “BCGitis” syn- 
drome,9 miliary tuberculosis,iO~ll and systemic dissemi- 
nation.12 Rarely, fatal outcomes have been reported.13 
The patient described in this case report clearly 
demonstrated a rare complication of BCG immunother- 
apy His disease pattern included mycobacteremia, pneu- 
monia, hepatitis, diffuse intravascular coagulation, and 
shock. He is a young man in generally good health, and 
this was his first intravesical instillation of BCG; there- 
fore, he was not presensitized to BCG, as would be 
expected after multiple treatments. He had no immuno- 
logic deficiencies, and his rapid deterioration was remark- 
able. Once the diagnosis was suspected, treatment 
included three antituberculous drugs, because of his 
extremely poor clinical status. The literature suggests that 
isoniazid therapy alone would have been adequate. 
Although the sensitivities of both the BCG strain and the 
blood culture isolate from the patient confirmed that in 
1991 this would have been adequate therapy, this may not 
be true in the future, owing to developing drug resistance. 
The use of high-performance liquid chromatography 
and simultaneous cultures of the blood isolate and the 
BCG companion vial isolate in this case confirmed that 
the organism causing the sepsis was the organism used 
for BCG immunotherapy The “BCGitis” syndrome seen 
in this case was not an allergic reaction to the mycobac- 
terium, but an invasive mycobacteremia. 
This patient’s follow-up has now extended over 5 
years, and repeated cystoscopic evaluations have failed to 
reveal tumor recurrence. He has remained healthy and 
fully functional. His PPD and HIV-l antibody remain neg- 
ative. It would appear that a single episode of BCG 
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immunotherapy, one that was associated with an exu- 
berant systemic reaction and major morbidity, was suc- 
cessful in preventing tumor recurrence over the past 5 
years. 
This case illustrates a serious potential complication 
of BCG immunotherapy. Patients developing complica- 
tions temporally related to BCG instillation should, after 
appropriate cultures, be treated with isoniazid with or 
without additional drugs while the diagnosis is being 
clarified. Surveillance for isoniazid resistance among BCG 
isolates may be required in the future. 
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